ClinicalTrials.gg
Active, not recruitingNCT02213926Updated Aug 4, 2026Results posted

An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma

A Phase 2 interventional study of ACP-196 (acalabrutinib) in Mantle Cell Lymphoma (MCL), sponsored by Acerta Pharma BV. Active, not recruiting at 58 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-04.

Sponsored by Acerta Pharma BV (part of AstraZeneca) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
124
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing acalabrutinib in Lymphoma, Mantle-Cell — 5 open to participants now, 20 under way, 1 of them phase 3. acalabrutinib · Lymphoma, Mantle-Cell.

Enrollment
4th of 26
124 · median 49
Started
2015
with 1 other
Phase 2
17 of 26
4 open now
Primary completion
2020-12
later than 0 of 19 live
Registered
1st of 26
by date
Lead sponsor
5 of 26
Acerta Pharma BV

Among the 26 studies testing acalabrutinib in Lymphoma, Mantle-Cell, this one is the 4th largest by enrollment, is one of 2 that started in 2015, is one of 17 in phase 2, reaches primary completion later than 0 of the 19 other live ones, and was the 1st registered.

Lymphoma, Mantle-Cell

1,221 studies on the registry are indexed under Lymphoma, Mantle-Cell; 155 are open to participants now.

Browse Lymphoma, Mantle-Cell studies →

Open to participants now

5 of the 26 studies testing acalabrutinib in Lymphoma, Mantle-Cell are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About acalabrutinib

acalabrutinib: first FDA approval 2017 (CALQUENCE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 125 Lymphoma, Mantle-Cell studies recruiting now, 92 (74%) set no upper age limit and 12 (10%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing acalabrutinib in Lymphoma, Mantle-Cell, or all of them as a file.
02

Study summary

The purpose of this study is to characterize the safety and efficacy profile of ACP-196 (acalabrutinib) in subjects with relapsed or refractory Mantle Cell Lymphoma (MCL).

Read the detailed description

This clinical trial is a Phase 2, multicenter, (approximately 70 global centers), open-label study in subjects with histologically documented MCL, who have relapsed after, or were refractory to, ≥ 1 (but not > 5) prior treatment regimens. Subjects will be enrolled and will take 100 mg of acalabrutinib twice per day (BID) in repeated 28-day cycles.

Treatment with acalabrutinib may be continued until disease progression or an unacceptable drug-related toxicity occurs. Dose modification provisions are provided in the study protocol.

All subjects will have hematology, chemistry, and urinalysis safety panels done at screening. Once dosing commences (Day 1), all subjects will be evaluated for safety, including serum chemistry and hematology, once weekly for the first 4 weeks, every 2 weeks in Cycle 2, every 4 weeks in Cycles 3 to 12, and every 24 weeks thereafter. PK/PD testing will be done in Cycles 1 and 2. Tumor assessments will be completed at 8- to 24-week intervals during the trial.

03

Conditions studied

  • Mantle Cell Lymphoma (MCL)

Keywords

  • Bruton tyrosine kinase inhibitor
  • Btk
  • Mantle Cell Lymphoma
  • MCL
  • ACP-196
  • Acalabrutinib
  • ACE-LY-004
  • Calquence
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women ≥ 18 years of age.
  • confirmed MCL, with documentation of monoclonal B cells that have a chromosome translocation t(11;14)(q13;q32) and/or overexpress cyclin D1.
  • (ECOG) performance status of ≤ 2.
  • Agreement to use during the study and for 30 days after the last dose of study drugs if sexually active and able to bear or beget children.

Exclusion criteria

Exclusion criteria:

  • A life-threatening illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of ACP-196 (acalabrutinib), or put the study outcomes at undue risk
  • Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening, or any Class 3 or 4 cardiac disease as defined by the Functional Classification, or interval (QTc) > 480 msec.
  • Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel or ulcerative colitis, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction.
  • Breast feeding or pregnant
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
124 participants (actual)

Study arms

  • Experimental
    ACP-196 (acalabrutinib) Regimen 1

    ACP-196 (acalabrutinib) Regimen 1

    Drug: ACP-196 (acalabrutinib)

Interventions

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR) of ACP-196 (Acalabrutinib) in Subjects With Previously Treated MCL.

    The overall response rate (ORR) is defined as the proportion of subjects achieving either a partial remission (response) (PR) or complete response (CR) according to the Lugano Classification for NHL (Cheson 2014) as assessed by investigators, where SD stands for Stable Disease, PD for Progressive Disease and NE for Not Evaluable.

    Time frame: From the date of the first dose until 30 days after the last dose of the study drug or start of a new anti-cancer treatment, whichever came first, assessed up to approximately 4 year and 10 months. 1 cycle =28 days

07

Results

Posted Oct 19, 2018

Participant flow

Participant flow — Overall Study
MilestoneACP-196 100 mg BID
Started124
Completed0
Not completed124
Withdrew: Death59
Withdrew: Withdrawal by subject10
Withdrew: Study terminated by sponsor51
Withdrew: Lost to follow-up3
Withdrew: Site closure - pi retirement1

Outcome measures

PrimaryOverall Response Rate (ORR) of ACP-196 (Acalabrutinib) in Subjects With Previously Treated MCL.

The overall response rate (ORR) is defined as the proportion of subjects achieving either a partial remission (response) (PR) or complete response (CR) according to the Lugano Classification for NHL (Cheson 2014) as assessed by investigators, where SD stands for Stable Disease, PD for Progressive Disease and NE for Not Evaluable.

Time frame:
From the date of the first dose until 30 days after the last dose of the study drug or start of a new anti-cancer treatment, whichever came first, assessed up to approximately 4 year and 10 months. 1 cycle =28 days
Reported as:
Count of participants · Participants
Overall Response Rate (ORR) of ACP-196 (Acalabrutinib) in Subjects With Previously Treated MCL.
ParticipantsACP-196 (Acalabrutinib)
CR59
PR42
SD10
PD10
NE3

Adverse events

Collected over From the date of the first dose until 30 days after the last dose of the study drug or start of a new anti-cancer treatment, whichever came first, assessed up to approximately 4 year and 10 months.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ACP-196 100 mg BID59/124 (47.6%)62/124 (50%)122/124 (98.4%)
Most frequent serious events
Showing 10 of 86
Most frequent serious events
EventACP-196 100 mg BID
PneumoniaInfections and infestations8/124
AnaemiaBlood and lymphatic system disorders6/124
General physical health deteriorationGeneral disorders4/124
ColitisGastrointestinal disorders2/124
Gastrointestinal haemorrhageGastrointestinal disorders2/124
VomitingGastrointestinal disorders2/124
PyrexiaGeneral disorders2/124
SepsisInfections and infestations2/124
Upper respiratory tract infectionInfections and infestations2/124
Tumour lysis syndromeMetabolism and nutrition disorders2/124
Most frequent other events
Showing 10 of 374
Most frequent other events
EventACP-196 100 mg BID
HeadacheNervous system disorders48/124
DiarrhoeaGastrointestinal disorders47/124
FatigueGeneral disorders37/124
CoughRespiratory, thoracic and mediastinal disorders29/124
NauseaGastrointestinal disorders27/124
MyalgiaMusculoskeletal and connective tissue disorders27/124
AstheniaGeneral disorders22/124
ConstipationGastrointestinal disorders20/124
Upper respiratory tract infectionInfections and infestations20/124
PyrexiaGeneral disorders19/124

Baseline characteristics

The analysis population included All Treated Subjects.

Age, Continuous
Age, Continuous(Years)ACP-196 100 mg BID
Mean67.1 ± 10.5
Sex: Female, Male
Sex: Female, Male(Participants)ACP-196 100 mg BID
Female25
Male99
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)ACP-196 100 mg BID
Hispanic or Latino4
Not Hispanic or Latino90
Not Reported30
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)ACP-196 100 mg BID
American Indian or Alaska Native0
Asian0
Black or African American3
Native Hawaiian or Other Pacific Islander0
White92
Not Reported29
Region of Enrollment
Region of Enrollment(Participants)ACP-196 100 mg BID
Australia2
Belgium2
France26
Italy8
Netherlands5
Poland19
Spain4
United Kingdom13
USA45
08

Study locations

58 sites
  • Research Site
    Tampa, Florida 33612, United States
  • Research Site
    Chicago, Illinois 60612, United States
  • Research Site
    Niles, Illinois 60714, United States
  • Research Site
    Peoria, Illinois 61615, United States
  • Research Site
    Boston, Massachusetts 2215, United States
  • Research Site
    Hackensack, New Jersey 07601, United States
  • Research Site
    New York, New York 10021, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    Seattle, Washington 98109, United States
  • Research Site
    Monash, Australia
  • Research Site
    Sydney, 2139, Australia
  • Research Site
    Wodonga, 3690, Australia
  • Research Site
    Bruges, 8000, Belgium
  • Research Site
    Brussels, 1000, Belgium
  • Research Site
    Brussels, 1200, Belgium
  • Research Site
    Liège, 4000, Belgium
  • Research Site
    Yvoir, 5530, Belgium
  • Research Site
    Prague, 100 34, CZ, Czechia
  • Research Site
    Angers, 49033, France
  • Research Site
    Caen, 14033, France
  • Research Site
    Clermond Ferrand, 63003, France
  • Research Site
    Créteil, 94010, France
  • Research Site
    Dijon, 21000, France
  • Research Site
    Grenoble, 38043, France
  • Research Site
    La Roche - Sure-Yon, 85925, France
  • Research Site
    Lille, 59000, France
  • Research Site
    Montpellier, 34295, France
  • Research Site
    Nantes, 44093, France
  • Research Site
    Paris, 75015, France
  • Research Site
    Paris, 75651, France
  • Research Site
    Pessac, 33604, France
  • Research Site
    Pierre-Bénite, 69310, France
  • Research Site
    Rennes, 35033, France
  • Research Site
    Rouen, 76038, France
  • Research Site
    Saint-Priest-en-Jarez, 42270, France
  • Research Site
    Strasbourg, 67098, France
  • Research Site
    Toulouse, 31100, France
  • Research Site
    Tours, 37000, France
  • Research Site
    Vandœuvre-lès-Nancy, 54500, France
  • Research Site
    Bologna, 40138, Italy
  • Research Site
    Meldola, 47014, Italy
  • Research Site
    Milan, 20132, Italy
  • Research Site
    Novara, 28100, Italy
  • Research Site
    Amsterdam, 1105 AZ, Netherlands
  • Research Site
    Maastricht, 6202 AZ, Netherlands
  • Research Site
    Rotterdam, 3062 PA, Netherlands
  • Research Site
    Krakow, 30-727, Poland
  • Research Site
    Lodz, 93-510, Poland
  • Research Site
    Olsztyn, 10-228, Poland
  • Research Site
    Badalona, 8916, Spain
  • Research Site
    Pamplona, 31008, Spain
  • Research Site
    Cardiff, CF14 4XW, United Kingdom
  • Research Site
    Leeds, LS9 7TF, United Kingdom
  • Research Site
    Leicester, LE1 7RH, United Kingdom
  • Research Site
    Nottingham, NG5 1PB, United Kingdom
  • Research Site
    Oxford, 0X3 7LE, United Kingdom
  • Research Site
    Plymouth, PL6 8DH, United Kingdom
  • Research Site
    Southampton, SO16 6YD, United Kingdom
09

References and documents

Publications

  • Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, Damaj G, Doorduijn J, Lamy T, Morschhauser F, Panizo C, Shah B, Davies A, Eek R, Dupuis J, Jacobsen E, Kater AP, Le Gouill S, Oberic L, Robak T, Covey T, Dua R, Hamdy A, Huang X, Izumi R, Patel P, Rothbaum W, Slatter JG, Jurczak W. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet. 2018 Feb 17;391(10121):659-667. doi: 10.1016/S0140-6736(17)33108-2. Epub 2017 Dec 11. PubMed 29241979 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2015 to primary completion in Dec 2020, 69 months.

Of 30 industry-sponsored phase 2 interventional studies under Lymphoma, Mantle-Cell, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's 69 months is above that.

Counting every sponsor, half of 183 studies reached it within 63 months; a quarter within 38 and three quarters within 106.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2014
First posted
Aug 12, 2014
StartActual
Mar 2, 2015
Primary completionActual
Dec 4, 2020
CompletionEst.
Sep 6, 2026
Results first posted
Oct 19, 2018
Last update
Aug 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02213926
Lead sponsor
Acerta Pharma BV
Responsible party
Sponsor
First posted
Aug 12, 2014
Start date
Mar 2, 2015
Primary completion
Dec 4, 2020
Completion
Sep 6, 2026 (estimated)
Results posted
Oct 19, 2018
Last update
Aug 4, 2026

Study contacts

Acerta Pharma
study director · 1-888-292-9613

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acalabrutinib

Start the discussion